Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Debt to Equity (2016 - 2025)

Historic Debt to Equity for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $0.24.

  • China Pharma Holdings' Debt to Equity fell 3779.29% to $0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.24, marking a year-over-year decrease of 3779.29%. This contributed to the annual value of $0.33 for FY2024, which is 414.76% down from last year.
  • Latest data reveals that China Pharma Holdings reported Debt to Equity of $0.24 as of Q3 2025, which was down 3779.29% from $0.42 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Debt to Equity high stood at $1.08 for Q3 2022, and its period low was $0.24 during Q3 2025.
  • For the 5-year period, China Pharma Holdings' Debt to Equity averaged around $0.52, with its median value being $0.42 (2025).
  • Per our database at Business Quant, China Pharma Holdings' Debt to Equity surged by 10064.41% in 2022 and then crashed by 6342.72% in 2023.
  • Quarter analysis of 5 years shows China Pharma Holdings' Debt to Equity stood at $0.72 in 2021, then dropped by 20.9% to $0.57 in 2022, then crashed by 39.98% to $0.34 in 2023, then decreased by 4.15% to $0.33 in 2024, then decreased by 28.13% to $0.24 in 2025.
  • Its Debt to Equity was $0.24 in Q3 2025, compared to $0.42 in Q2 2025 and $0.37 in Q1 2025.